Kornimate/medical-research-clean huggingface dataset:
obdiphy (obesity digital-physical care study)

Conditions: Pediatric Obesity; Obesity; Adolescent Obesity; Lifestyle Risk Reduction; Metabolic Syndrome; Weight Loss

Summary: this is a prospective randomized controlled multicentre non-inferiority trial. the aim of this study to evaluate digi-physical care compared to regular physical/in person care and investigate if digi-physical care can be an equal or even better treatment alternative among families with children or adolescents living with obesity in sweden. the study participants will either get treatment as usual or treatment as usual combined with digi-physical solution. the digi-physical solution includes thar half of the session is digital and they get an app where they can self-monitoring health data, have an overview over they treatment plan and easy communicate with theirs caregivers.

this study is multi centre in three different county council in southwest of sweden which include children and adolescents in the age of 10-16 year. the study participants will either get treatment as usual, which includes four in person session with healthcare professionals as doctor, nurse or dietitian (the control group) or treatment as usual combined with digi-physical solution (intervention group). the intervention group will beyond treatment as usual get a digital communication platform (including an app) where the patient has a good overview of their treatment plan, can report self-monitored health data as daily steps and weight once a week and monitor the daily work with their selected health goal. everything in the app is individually tailored together with the patient. the patient with digi-physical care will also have assess to a chat for communication with their caregivers. the app has a high degree of authentication and classified as a journal system. half of yearly treatment as usual sessions will be digital for the intervention group. the digi-physical method of treatment is developed and based on the desire from the patient association hobs (hälsa oberoende av storlek). in parts of sweden people have long distance to the clinic which makes it difficult to be present at the treatment in-clinic sessions and the families loses many hours away from school and work. the null hypothesis is that digi-physical care will have a positive effect on bmi sds, however inferior to treatment as usual. in addition to evaluate that this new treatment alternative is safe will also iso-bmi, weight development and metabolic risk factors be evaluated. the study does not include any extra blood samples or visits to the clinic thus everything is collected according to regular care programs. to evaluate the food intake and possible changes there will be three 24-h recalls, combined with riksmaten flex, performed. there will also be questions about their physical activity and a survey (peds-ql) for mental health. for a few volunteered patient families, approximate 15-20, will participate in semi-structured deep interviews.

Eligibility criteria:
inclusion criteria: * iso-bmi 30 or above. exclusion criteria: * lack of swedish skills * patients potential for obesity surgery * patient with obesity syndrome
hyoscine butyl-bromide versus ondansetron for nausea and vomiting during cesarean section under spinal anesthesia

Conditions: Vomiting

Summary: overall incidence of intraoperative nausea and vomiting(ionv) during regional anesthesia for cesarean section is extremely variable, up to 80 percent , depending on the anesthetic technique used (spinal, epidural or combined spinal-epidural) and on the preventive and therapeutic measures taken.1 spinal anesthesia for cs is safe and effective; it is currently the anesthetic technique of choice for elective cesarean delivery (cd). however, maternal hypotension associated with spinal anesthesia is one of the primary causes of intraoperative nausea and/or vomiting (ionv); this symptom is thought to be caused by cerebral and gut hypoperfusion that stimulate the vomiting centre in the brainstem and cause serotonin release, respectively.2, 3 while bolus dosing of phenylephrine effectively treats maternal hypotension, it does not prevent intraoperative maternal nausea, which may be associated with established hypotension, and this may adversely affect patient satisfaction.4, 5 however, the unopposed vagal activity that occurs with sympathetic block might be another cause of intraoperative nausea and vomiting during spinal anesthesia.6 both scopolamine and atropine are tertiary amines, which cross the blood-brain barrier with central side effects, such as confusion, sedation, or paradoxical excitation. however, hyoscine butyl bromide (hbb) has a quaternary ammonium structure that does not cross through the blood-brain barrier and also with lower placental transfer than atropine, making it more suitable for use in pregnancy 7, 8. hyoscine butyl-bromide, also known as scopolamine butyl-bromide and sold under the brand name buscopan.9 despite being a quaternary ammonium compound, hbb is still capable of targeting the chemoreceptor trigger zone due to the lack of a well-developed blood-brain-barrier in the medulla oblongata, which potentiates the antiemetic effects that it produces through local action on the smooth muscle of the gastrointestinal tract.10 so, the aim of the current study is to examine the effect of prophylactic use of hbb and ondansetron to decrease the incidence of intraoperative bradycardia and thus intraoperative nausea and vomiting in parturients undergoing cd under spinal anaesthesia.


Eligibility criteria:
inclusion criteria: * all patients 18-40 years of age, * american society of anaesthesiologists (asa) classification class i and ii * patients scheduled for elective or semi-elective surgery (category 3 and 4 caesarean section) under spinal anaesthesia * single baby pregnancy of more than 32 weeks exclusion criteria: * height \ 180 cm, * body mass index (bmi) \>35 kg m-2, * contraindication or refusal to undergo regional anaesthesia, * any cardiovascular disease including arrhythmias, patients on β-adrenergic blockers or any drugs that may alter the normal response to the study drug, * history of ponv or motion sickness, * had taken antiemetic medication in the previous week, * had a history of hyperemesis gravidarum
ctag dissection/trauma post marketing surveillance japan

Conditions: Thoracic Aortic Aneurysm; Thoracic Aorta Injury; Thoracic Aortic Dissection

Summary: post marketing surveillance of the conformable gore® tag® thoracic endoprosthesis


Eligibility criteria:
inclusion criteria for acute, complicated stanford type b aortic dissection: * patient present with acute complicated type b aortic dissection * patient who do not respond to medical therapy * time from symptom onset to dissection diagnosis ≤ 14 days * adequate iliac / femoral access or conduit * aortic inner diameter at proximal extent of proximal landing zone in the range of 16-42 mm * ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected inclusion criteria for traumatic aortic transection: * patient has traumatic aortic transection that requires repair as determined by treating physician * adequate iliac / femoral access * aortic inner diameter in the range of 16-42 mm on the proximal and distal sides * ≥ 20 mm non-aneurysmal aorta neck proximal and distal to the lesion
cochlear implants : influence of microphone aging and dirtying

Conditions: Hard of Hearing

Summary: cochlear implant microphones are subject to aging and dirtying. the evolution may affect their efficiency. several signal coding strategies are used in cochlear implants and their behaviour may be more or less affected by the aging process. in this work the investigators wish to assess this phenomenon.


Eligibility criteria:
inclusion criteria: * french speaking persons (french native speakers; studies made in french) * ear, nose and throat (ent) tests and check up for normal hearing listeners were normal (hearing loss below 20 dbs for all frequencies situated in the 250-8000 hz range) * not mentally retarded exclusion criteria: * persons with tinnitus or headache * anxious people (taking psychiatric drugs) * mental alteration or mental retard * deafened persons or taking an ent treatment (normal hearing listeners)
"generation fit and exerlearning with in the groove"

Conditions: Obesity

Summary: in middle schools participating in a statewide program called "take time", we are randomizing youth to a 10-12 week intervention using the dance mat games on the playstation2 (like dance dance revolution). this program is testing feasibility of using the dance mats as a way to increase activity during the school day. we are using "groove masters" as a peer-mentored mechanism to keep track of the activity of youth in the intervention compared to the control group. our main objective is increase in activity time.

we met with administrators and teachers and obtained consent and assent for this study. after assessing baseline measures (end-of-grade test scores, absenteeism, pediatric quality of life, physical fitness, gems activity rating scale, dennison's measure of sedentary screen time, physical activity enjoyment scale, bmi%ile, (with a small subset assayed for fasting lipids and glucose, with a smaller subset wearing actigraphs for objective measures of activity) we randomized to the intervention or control group. in our intervention, youth play a dance game at school called "in the groove", with the goal of 40 additional minutes each week of physical activity during the school hours. we will obtain change scores and compare the groups to find an effect size for future studies, this this proves acceptable and feasible in maine schools.

Eligibility criteria:
inclusion criteria: * take time middle school in maine with consent/assent exclusion criteria: * any condition that prevents a child from doing physical activity on the dance mat like photic seizures, broken leg, blindness.

Keywords: dance peers middle school-based feasibility
does abatacept induce regulatory b cells in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: abatacept disrupts t-cell coactivation signals in rheumatoid arthritis (ra). its potential effects on b cells are not well described. this study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood b cells in patients with ra.


Eligibility criteria:
inclusion criteria: * ra as defined by acr/eular criteria * clinical indication to start abatacept therapy exclusion criteria: * treatment by rituximab in the previous year
effectiveness of the tiger catheter on transradial coronariography: randomized compared to judkins catheters

Conditions: Acute Coronary Syndrome

Summary: the aim of this study was to assess effectiveness and safety of tiger (5fr) vs judkins (5fr) catheters, in coronariography via the right transradial approach. this was a prospective, randomized, study of paralled design. consecutive patients with acute coronary syndrome (acs), eligible for coronary angiography, was randomized after successuful cannulation of right artery and informed consent to either tiger or judkins catheters.

analyzed a total of 120 consective diagnostic coronary angioggraphy cases from the right radial approach. of these 60 cases were performed with single catheter (tiger) and 60 cases were performed with conventional catheters (judkins). the patients of both group were overall well balanced for gender, age, risk factors, height, weight and body surface area. diagnostic angiograms were successfully achieved in all cases via the radial approach.

Eligibility criteria:
inclusion criteria: * written informed consent * indication for coronary angiography exclusion criteria: * negative allen´s test * chronic renal failure (to preserve the right radial artery for potencial arteriovenous shunting) * hemodynamic instability * coronary artery bypass grafting

Keywords: coronary angiography diagnosctic transradial catheter transradial catheter
experimental study of the impact of a group therapy psychological intervention for caregivers of alzheimer's disease patients

Conditions: Psychological Support to Caregivers of Azlheimer's Patients

Summary: a randomized controlled trial designed to test the effectiveness of a psychological intervention based on group therapy for the caregivers of alzheimer's disease patients. the intervention consists of 14 sessions of a cognitive-behavioral psychological group therapy. this study aims to demonstrate that alzheimer's patients' caregivers can benefit from group counseling, with an improvement in mood state, quality of life, perceived burden and a decrease in anxiety and depression. two evaluations will be done: before the therapy sessions (basal) and when intervention is finished (final).

the aim of this study is to conduct group therapy with alzheimer's caregivers at three centers in the province of barcelona: hospital el carme badalona, sanitary center of les corts and sarrià. the therapy sessions are conducted by an expert in group therapy (from the sponsor pasqual maragall foundation) and the social worker of each of the centers. the study takes place for four months and consists of weekly therapy sessions of an hour and a half each (14 sessions in total), based on cognitive and behavioral theory. the participants and the control group are evaluated at the beginning and at the end of the study in terms of mood, quality of life, anxiety and depression. this study aims to demonstrate that alzheimer's patient's caregivers can benefit from group counseling, resulting in an improvement in their emotional state, perceived burden, quality of life and a more positive attitude coping with the new situation.

Eligibility criteria:
inclusion criteria: * to be the principal caregiver of a person with alzheimer's disease * the patient has a possible or probable diagnosis of alzheimer's disease made for an accredited dementia unit. * the patient score in the global deterioration scale must be: 4, 5 or 6a. * the caregiver must dedicate at least 5 hours a day or spend a significant part of his time to care-related tasks * the caregiver must sign the informed consent exclusion criteria: * to receive a financial compensation for the care of the patient * the caregiver or the patient has a psychiatric illness according to the dsm-iv tr, such that the investigator considers it might hinder the dynamics of the group and affect the objectives of the study * be receiving some type of formal counseling (conducted by a therapist

Keywords: group cognitive behavior therapy, alzheimer's disease, caregivers¡
role of proteomics and metallomics in cerebral vasospasm following subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Cerebral Vasospasm; Hydrocephalus

Summary: the purpose of this study is to determine the role of proteomics and metallomics in cerebral vasospasm following subarachnoid hemorrhage


Eligibility criteria:
inclusion criteria: * non traumatic sah documented by ct scan * patient with sah who would need external ventricular drain (evd) for the management of hydrocephalus * patients with normal pressure hydrocephalus that require an external drain * control (non - hemorrhagic) group - csf collected from patients with posterior fossa tumor or stroke with evd in place for the management of hydrocephalus. exclusion criteria: * recent infection within last 1 month of presentation- can increase inflammatory markers * recent surgery or acute myocardial infarction within last 1 month of presentation * age \> 89 years or \< 18 years

Keywords: xanthine oxidase cerebrospinal fluid
self-help for treating social anxiety disorder: an evaluation of a mindfulness and acceptance-based approach

Conditions: Anxiety; Shyness

Summary: social anxiety disorder (sad) is the most common anxiety disorder, affecting up to 10% of the population and causing significant distress. fortunately, there are effective interventions including cognitive behavior therapy (cbt) and acceptance and commitment therapy (act). however, only about a third of people with sad seek treatment. there are a number of barriers to seeking treatment, including cost, availability, and stigma. self-help may be one way to reach people who may not otherwise present for treatment. research on self-help books for sad based on cbt has yielded promising results. however, no research to date has examined the efficacy of act-based self-help for sad. the primary purpose of the present study is to evaluate the mindfulness and acceptance-based workbook for social anxiety and shyness (fleming \& kocovski, 2013), an act-based self-help book. socially anxious participants will be randomly assigned to receive the workbook or be placed on a waitlist. it is hypothesized that workbook participants will report significantly reduced social anxiety at the end of eight weeks compared to waitlist participants. the secondary purpose is to evaluate how the treatment works. increases in mindfulness and acceptance have been shown to lead to reduced social anxiety. these same variables will be examined in the present study. finally, this research aims to examine variables that can predict who may do well in treatment. given that two-thirds of people who meet criteria for this disorder will not seek traditional treatments, it is important to develop and evaluate alternative treatments, including those based on self-help.


Eligibility criteria:
inclusion criteria: * must be seeking help for shyness/social anxiety exclusion criteria: -
outcome of treating bladder cancer in sohag university hospital

Conditions: Bladder Cancer

Summary: retrospective study of outcome of urinary bladder cancer treated in sohag university hospital in the past 5 years from 2016 to 2020

this study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer

Eligibility criteria:
inclusion criteria: * all stages and grades of urinary bladder cancer any histological types of urinary bladder cancer exclusion criteria: * presence of other malignancies
comparison of clomid and lezra with lezra for ovulation induction in clomid resistant pcos case

Conditions: Polycystic Ovarian Syndrome

Summary: clomiphene citrate resistant i.e failure to ovulate after 6 cycles of ovulation induction effects 15-40% of patients with pcos.two treatment groups will be formed one recieving letrozole alone and another recieving cc and letrozole combined.mature follicles and endometrial thickness will be checked by transvaginal ultrasound and results will be recorded.

subfertility is characterized by the inability to achieve conception despite engaging in regular unprotected sexual intercourse for 1-2 years.pcos exhibits chacteristic traits such as obesity,heightened insulin resistance accompanied by compensatory hyperinsulinemia,oligo/anovulation and subfertility.clompiphene citrate induces ovarian stimulation.letrozole ,an aromatase inhibitor emerges as a novel medication with comparable efficacy to cc as a first line treatment for inducing ovulation in cases of anovulation.

Eligibility criteria:
inclusion criteria: * women of 20-40 years with a history of pcos and resistant to cc exclusion criteria: * premature ovarian insufficiency * husband has oligo azoospermia * hypothyroidism * hyperprolactinemia
post- myocardial infarction arterial wall improvement by low-dose fluvastatin and valsartan

Conditions: Myocardial Infarction

Summary: the concept of improving arterial wall characteristics by treatment with a very low-dose combination of fluvastatin and valsartan (low-flu/val) in stable, post-myocardial infarction (mi) patients was tested. the parameters of endothelial function (flow mediated dilatation (fmd), reactive hyperemia index) and arterial stiffness (carotid-femoral pulse wave velocity (cf-pwv), local carotid pwv and β-stiffness coefficient) were measured before and after 30 days of treatment, and the residual effect was assessed 10 weeks later. so the investigators explored whether low-flu/val added "on-top-of" optimal therapy could improve endothelial function and arterial stiffness in post-mi patients. since these improved parameters are well-known predictors of future coronary events, such treatment could decrease cardiovascular risk.


Eligibility criteria:
inclusion criteria: * history of mi in the last 0.5 to 5 years * males * aged under 55 years exclusion criteria: * diabetes mellitus * manifest peripheral artery disease or carotid artery disease * acute infection * chronic diseases * present therapy with fluvastatin and/or valsartan.

Keywords: myocardial infarction arterial stiffness pulse wave velocity flow mediated dilatation fluvastatin valsartan
performance characteristics and safety assessment of a non-invasive glucose monitoring device

Conditions: Diabetes Mellitus

Summary: this clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

subjects will collect spectral raman data on device every 15 minutes for 10 hours a day for five days. the five days will be distributes with in a timeframe of ten days. a flash glucose monitor will be used as a comparator. in addition to this, four daily capillary blood glucose readings will be collected.

Eligibility criteria:
inclusion criteria: * male and female subjects 18 years of age or older * diabetic patients (all types) exclusion criteria: * pregnant women * subjects not able to understand and read danish * in investigator's opinion, subject is not able to follow instructions as specified in the protocol * subjects not able to hold hand/arm steadily * extensive skin changes, tattoos or diseases on probe application site * known allergy to medical grade alcohol used to disinfect skin
safety and immunogenicity study of two doses of novartis meningococcal serogroup b recombinant vaccine in adolescents aged 11-17 years.

Conditions: Meningococcal Disease

Summary: the purpose of the study was to assess the immunogenicity and safety of two doses of novartis meningococcal b recombinant (rmenb+omv nz) vaccine administered one month apart (0, 1 month schedule) in korean adolescents aged between 11 to 17 years.


Eligibility criteria:
inclusion criteria: 1. adolescents 11-17 years of age inclusive who have given their written assent and whose parent or legal guardian has given written informed consent at the time of enrollment; 2. available for all the visits scheduled in the study (i.e. not planning to leave the area before the end of the study period); 3. in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator; 4. with a negative urine pregnancy test (for female subjects only). exclusion criteria: 1. history of any meningococcal vaccine administration; 2. current or previous, confirmed or suspected disease caused by n. meningitidis; 3. household contact with and/or intimate exposure to an individual with any laboratory confirmed n. meningitidis infection within 60 days of enrollment; 4. pregnancy or nursing (breastfeeding) mothers; 5. female subjects who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study; 6. any serious chronic or progressive disease; 7. family members and household members of research staff; 8. any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives; 9. significant acute or chronic infection within the previous 7 days or fever within 3 days prior to enrolment; 10. antibiotics within 6 days prior to enrollment; 11. known or suspected impairment/alteration of the immune system, immunosuppressive therapy; 12. receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days; 13. history of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component; 14. receipt of or intent to immunize with any other vaccine(s) within 30 days prior and throughout the study period; 15. participation in another clinical trial within the last 90 days or planned for during study.

Keywords: meningitis, adolescents, meningococcal b